|
1
|
Hariharan D, Saied A and Kocher HM:
Analysis of mortality rates for pancreatic cancer across the world.
HPB (Oxford). 10:58–62. 2008.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Garrido-Laguna I and Hidalgo M: Pancreatic
cancer: From state-of-the-art treatments to promising novel
therapies. Nat Rev Clin Oncol. 12:319–334. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Adamska A, Domenichini A and Falasca M:
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.
Int J Mol Sci. 18(E1338)2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620.
2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: Rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Friedman RC, Farh KKH, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Garofalo M and Croce CM: microRNAs: Master
Regulators as Potential Therapeutics in Cancer. Annu Rev Pharmacol
Toxicol. 51:25–43. 2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zhang Y, Li M, Wang H, Fisher WE, Lin PH,
Yao Q and Chen C: Profiling of 95 microRNAs in pancreatic cancer
cell lines and surgical specimens by real-time PCR analysis. World
J Surg. 33:698–709. 2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Khan MA, Zubair H, Srivastava SK, Singh S
and Singh AP: Insights Into the Role of microRNAs in Pancreatic
Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and
Therapy. Adv Exp Med Biol. 889:71–87. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wang Z, Wang N, Liu P, Chen Q, Situ H, Xie
T, Zhang J, Peng C, Lin Y and Chen J: MicroRNA-25 regulates
chemoresistance-associated autophagy in breast cancer cells, a
process modulated by the natural autophagy inducer
isoliquiritigenin. Oncotarget. 5:7013–7026. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhang H, Zuo Z, Lu X, Wang L, Wang H and
Zhu Z: miR-25 regulates apoptosis by targeting Bim in human ovarian
cancer. Oncol Rep. 27:594–598. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Feng S, Pan W, Jin Y and Zheng J: miR-25
promotes ovarian cancer proliferation and motility by targeting
LATS2. Tumour Biol. 35:12339–12344. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhao H, Wang Y, Yang L, Jiang R and Li W:
miR-25 promotes gastric cancer cells growth and motility by
targeting RECK. Mol Cell Biochem. 385:207–213. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Li BS, Zuo QF, Zhao YL, Xiao B, Zhuang Y,
Mao XH, Wu C, Yang SM, Zeng H, Zou QM, et al: MicroRNA-25 promotes
gastric cancer migration, invasion and proliferation by directly
targeting transducer of ERBB2, 1 and correlates with poor survival.
Oncogene. 34:2556–2565. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Li Q, Zou C, Zou C, Han Z, Xiao H, Wei H,
Wang W, Zhang L, Zhang X, Tang Q, et al: MicroRNA-25 functions as a
potential tumor suppressor in colon cancer by targeting Smad7.
Cancer Lett. 335:168–174. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wang C, Wang X, Su Z, Fei H, Liu X and Pan
Q: MiR-25 promotes hepatocellular carcinoma cell growth, migration
and invasion by inhibiting RhoGDI1. Oncotarget. 6:36231–36244.
2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Caiazza C and Mallardo M: The Roles of
miR-25 and its Targeted Genes in Development of Human Cancer.
MicroRNA. 5:113–119. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Deng T, Yuan Y, Zhang C, Zhang C, Yao W,
Wang C, Liu R and Ba Y: Identification of Circulating MiR-25 as a
Potential Biomarker for Pancreatic Cancer Diagnosis. Cell Physiol
Biochem. 39:1716–1722. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCT method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Song W, Li Q and Wang L and Wang L:
Modulation of FoxO1 expression by miR-21 to promote growth of
pancreatic ductal adenocarcinoma. Cell Physiol Biochem. 35:184–190.
2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Sun XJ, Liu BY, Yan S, Jiang TH, Cheng HQ,
Jiang HS, Cao Y and Mao AW: MicroRNA-29a Promotes Pancreatic Cancer
Growth by Inhibiting Tristetraprolin. Cell Physiol Biochem.
37:707–718. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Song B, Zheng K, Ma H, Liu A, Jing W, Shao
C, Li G and Jin G: miR-429 determines poor outcome and inhibits
pancreatic ductal adenocarcinoma growth by targeting TBK1. Cell
Physiol Biochem. 35:1846–1856. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Grove M, Demyanenko G, Echarri A, Zipfel
PA, Quiroz ME, Rodriguiz RM, Playford M, Martensen SA, Robinson MR,
Wetsel WC, et al: ABI2-deficient mice exhibit defective cell
migration, aberrant dendritic spine morphogenesis, and deficits in
learning and memory. Mol Cell Biol. 24:10905–10922. 2004.PubMed/NCBI View Article : Google Scholar
|
